Histidine catabolic process

Across TCGA pan-cancer cohorts, RNA activity of the Histidine catabolic process pathway differs between tumor and matched normal tissue in 11 of the 18 cancer types tested.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where pathway activity is lower in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as KIRP and KIRC, show the opposite pattern, with lower activity in tumor tissue.

KIRP, KIRC, and LIHC show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
KIRP	All	III,IV	−0.140	<.001	10	view →
KIRC	All	All	−0.090	<.001	9	view →
LIHC	Male	II,III,IV	−0.127	<.001	8	view →
COAD	All	All	+0.075	<.001	7	view →
HNSC	All	III,IV	−0.075	<.001	7	view →
BRCA	All	III,IV	+0.071	<.001	6	view →
CHOL	Female	All	−0.323	<.001	5	view →
THCA	Male	All	+0.078	.001	4	view →
LUSC	All	All	−0.038	.002	3	view →
LUAD	All	IV	−0.064	.005	2	view →
BLCA	Male	IV	+0.145	.032	1	view →

Pink = more active in tumor, green = less active in tumor. Showing the 11 strongest of 11 lineages.

GO:0006548–KIRP

Open the KIRP breakdown →